Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: A model for prostate cancer

Laboratory Investigation

Volumn 78, Issue 3, 1998, Pages 319-333

  Kasper, Susan ^a   Sheppard, Patricia C ^c   Yan, Yulin ^c   Pettigrew, Norman ^c   Borowsky, Alexander D ^a   Prins, Gail S ^b   Dodd, Janice G ^c   Duckworth, Mary Lynn ^c   Matusik, Robert J ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROBASIN; VIRUS LARGE T ANTIGEN;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL TRANSFORMATION; GROWTH REGULATION; HORMONAL REGULATION; MALE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TRANSGENIC MOUSE;

ANDROGEN-BINDING PROTEIN; ANDROGENS; ANIMALS; ANTIGENS, VIRAL, TUMOR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; MALE; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS;

EID: 0031883020     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Barrios R, Lebovitz RM, Wiseman AL, Weisoly DL, Matusik RJ, DeMayo F, and Lieberman MW (1996). RasT24 driven by a probasin promoter induces prostatic hyperplasia in transgenic mice. Transgenics 2:23-28.
2. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, and Allred DC (1993). p53 is mutated in a subset of advanced-ssmall t antigene prostate cancers. Cancer Res 53:3369-3373.
3. Bookstein R, Rio P, Madreperla SA, Hong F, Allred C, Grizzle WE, and Lee WH (1990a). Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci USA 87:7762-7766.
4. Bookstein R, Shew JY, Chen PL, Scully P, and Lee WH (1990b). Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247:712-715.
5. Bostwick DG (1994a). c-erbB-2 oncogene expression in prostatic intraepithelial neoplasia: Mounting evidence for a precursor role (editorial; comment). J Natl Cancer Inst 86:1108-1110.
6. Bostwick DG (1996). Prospective origins of prostate carcinoma. Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Cancer 78:330-336.
7. Bostwick DG, Burke HB, Wheeler TM, Chung LW, Bookstein R, Pretlow TG, Nagle RB, Montironi R, Lieber MM, Veltri RW, Grizzle WE, and Grignon DJ (1994b). The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials. J Cell Biochem 19(Suppl): 283-289.
8. Bostwick DG, Pacelli A, and Lopez-Beltran A (1996). Molecular biology of prostatic intraepithelial neoplasia. Prostate 29:117-134.
9. Brooks JD, Bova GS, Ewing CM, Piantadosi S, Carter BS, Robinson JC, Epstein JI, and Isaacs WB (1996). An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res 56:3814-3822.
10. Brooks JD, Bova GS, and Isaacs WB (1995). Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas. Prostate 26:35-39.
11. Culig Z, Hobisch A, Cronauer MV, Cato AC, Hittmair A, Radmayr C, Eberle J, Bartsch G, and Klocker H (1993a). Mutant androgen receptor detected in an advanced-ssmall t antigene prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7:1541-1550.
12. Culig Z, Klocker H, Eberle J, Kaspar F, Hobisch A, Cronauer MV, and Bartsch G (1993b). DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction. Prostate 22:11-22.
13. Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ, and Sugimura Y (1987). The endocrinology and developmental biology of the prostate. Endocr Rev 8:338-362.
14. Donjacour AA, Rosales A, Higgins SJ, and Cunha GR (1990). Characterization of antibodies to androgen-dependent secretory proteins of the mouse dorsolateral prostate. Endocrinology 126:1343-1354.
15. Dunning WF (1963). Prostate cancer in the rat. In: Vollmer EP and Kauffmann G, editors: Workshop on the biology of the prostate and related tissues. Washington DC: US Government Printing Office, 351-369.
16. Ferguson J, Zincke H, Ellison E, Bergstrahl E, and Bostwick DG (1994). Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with ssmall t antigene T3 carcinoma treated by radical prostatectomy. Urology 44:91-95.
17. Frost JA, Alberts AS, Sonsmall t antigen E, Guan K, Mumby MC, and Feramisco JR (1994). Simian virus 40 small t antigen cooperates with mitogen-activated kinases to stimulate AP-1 activity. Mol Cellular Biol 14:6244-6252.
18. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, and Srivastava S (1994). Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54:2861-2864.
19. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, and Greenberg NM (1997). Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 57: 4687-4691.
20. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM, and Greenberg NM (1996). Metastatic prostate cancer in a transgenic mouse. Cancer Res 56:4096-4102.
21. Graham SD Jr (1992). Critical assessment of prostate cancer ssmall t antigening. Cancer 70 (Suppl):269-274.
22. Graham SD Jr, Bostwick DG, Hoisaeter A, Abrahamsson P, Algaba F, di Sant'Agnese A, Mostofi FK, and Napalkov P (1992). Report of the Committee on Ssmall t antigening and Pathology. Cancer 70:359-361.
23. Green JE, Greenberg NM, Barrett JC, Boone CW, Getzenberg RH, Henkin J, Matusik RJ, Padley RJ, and Scher HI (in press, 1997). Transgenic and reconstitution models of prostate cancer. Prostate.
24. Greenberg NM, DeMayo FJ, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, and Rosen JM (1995). Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92:3439-3443.
25. Greenberg NM, DeMayo FJ, Sheppard PC, Barrios R, Lebovitz M, Finegold M, Angelopoulou R, Dodd JG, Duckworth ML, Rosen JM, and Matusik RJ (1994). The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol Endocrinol 8:230-239.
26. Grizzle WE, Myers RB, Arnold MM, and Srivastava S (1994). Evaluation of biomarkers in breast and prostate cancer. J Cell Biochem 19(Suppl):259-266.
27. Helpap BG, Bostwick DG, and Montironi R (1995). The significance of atypical adenomatous hyperplasia and prostatic intraepithelial neoplasia for the development of prostate carcinoma: An update. Virchows Arch 426:425-434.
28. Isaacs WB, Carter BS, and Ewing CM (1991). Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51:4716-4720.
29. Kelly WK and Scher HI (1993). Prostate specific antigen decline after antiandrogen withdrawal: The flutamide withdrawal syndrome. J Urol 149:607-609.
30. Klocker H, Culig Z, Hobisch A, Cato AC, and Bartsch G (1994). Androgen receptor alterations in prostatic carcinoma. Prostate 25:266-273.
31. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T, and Kallioniemi OP (1997). Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57:314-319.
32. Lee C (1996). Role of androgen in prostate growth and regression: Stromal-epithelial interaction (review). Prostate 6(Suppl):52-56.
33. Levine AJ (1990). Tumor suppressor genes. Bioessays 12: 60-66.
34. Levine AJ and Momand J (1990). Tumor suppressor genes: The p53 and retinoblastoma sensitivity genes and gene products. Biochim Biophys Acta 1032:119-136.
35. Lu J and Danielsen M (1996). Interaction between SV40 large tumor antigen and the androgen receptor. In: The 10th International Congress of Endocrinology program and abstracts. Bethesda: Endocrine Society, P1-212.
36. Maroulakou IG, Anver M, Garrett L, and Green JE (1994). Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci USA 91:11236-11240.
37. McNeal JE (1993). Prostatic microcarcinomas in relation to cancer origin and the evolution to clinical cancer. Cancer 71:984-991.
38. Mellon K, Thompson S, Charlton RG, Marsh C, Robinson M, Lane DP, Harris AL, Horne CH, and Neal DE (1992). p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J Urol 147:496-499.
39. Montironi R, Scarpelli M, Galluzzi CM, and Diamanti L (1992). Aneuploidy and nuclear features of prostatic intraepithelial neoplasia (PIN). J Cell Biochem 16H(Suppl):47-53.
40. Myers RB, Oelschlager D, Srivastava S, and Grizzle WE (1994a). Accumulation of the p53 protein occurs more frequently in metastatic than in localized prostatic adenocarcinomas. Prostate 25:243-248.
41. Myers RB, Srivastava S, Oelschlager DK, and Grizzle WE (1994b). Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J Natl Cancer Inst 86:1140-1145.
42. Nagle RB, Brawer MK, Kittelson J, and Clark V (1991). Phenotypic relationships of prostatic intraepithelial neoplasia to invasive prostatic carcinoma. Am J Pathol 138:119-128.
43. Newmark JR, Hardy DO, Tonb DC, Carter BS, Epstein JI, Isaacs WB, Brown TR, and Barrack ER (1992). Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 89:6319-6323.
44. Noble RL (1977). Sex steroids as a cause of adenocarcinoma of the dorsal prostate in Nb rats, and their influence on the growth of transplants. Oncology 34:138-141.
45. Noble RL (1980). Production of Nb rat carcinoma of the dorsal prostate and response of estrogen-dependent transplants to sex hormones and tamoxifen. Cancer Res 40:3547-3550.
46. Pallas DC, Shahrik LK, Martin BL, Jaspers S, Miller TB, Brautigan DL, and Roberts TM (1990). Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A. Cell 60:167-176.
47. Perez-Stable C, Altman NH, Brown J, Harbison M, Cray C, and Roos BA (1996). Prostate, adrenocortical, and brown adispose tumors in fetal globin T antigen transgenic mice. Lab Invest 74:363-373.
48. Perez-Stable C, Altman NH, Mehta PP, Deftos LJ, and Roos BA (1997). Prostate cancer progression, metastasis, and gene expression in transgenic mice. Cancer Res 57:900-906.
49. Pertschuk LP, Macchia RJ, Feldman JG, Brady KA, Levine M, Kim DS, Eisenberg KB, Rainford E, Prins GS, and Greene GL (1994). Immunocytochemical assay for androgen receptors in prostate cancer: A prospective study of 63 cases with long-term follow-up. Ann Surg Oncol 1:495-503.
50. Petein M, Michel P, van Velthoven R, Pasteels JL, Brawer MK, Davis JR, Nagle RB, and Kiss R (1991). Morphonuclear relationship between prostatic intraepithelial neoplasia and cancers as assessed by digital cell image analysis. Am J Clin Pathol 96:628-634.
51. Pollard M (1992). The Lobund-Wistar rat model of prostate cancer. J Cell Biochem 16H(Suppl):84-88.
52. Price D (1963). Comparative aspects of development and structure in the prostate. In: Vollmer EP and Kauffmann G, editors: Biology of the prostate and related tissues. Washington DC: US Government Printing Office, 1-28.
53. Prins GS, Woodham C, Lepinske M, and Birch L (1993). Effects of neonatal estrogen exposure on prostatic secretory genes and their correlation with androgen receptor expression in the separate prostate lobes of the adult rat. Endocrinology 132:2387-2398.
54. Schaffner DL, Barrios R, Shaker M, Rajagopalan S, Huang S, Tindall DJ, Young CYF, Overbeek PA, Lebovitz RM, and Lieberman MW (1995). Transgenic mice carrying a PSArasT24 hybrid gene develop salivary gland and Gl tract neoplasms. Lab Invest 72:283-390.
55. Shain SA and Koger JD (1989). Differences in responsiveness of clonally derived AXC/SSh rat prostate cancer cells to secreted or prototypic mitogens. Cancer Res 49:3898-3903.
56. Shibata MA, Maroulakou IG, Jorcyk CL, Gold LG, Ward JM, and Green JE (1996). p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: Suppression of apoptosis during the transition from preneoplasia to carcinoma. Cancer Res 56:2998-3003.
57. Sleigh MJ, Topp WC, Hanich R, and Sambrook JF (1978). Mutants of SV40 with an altered small t protein are reduced in their ability to transform cells. Cell 14:79-88.
58. Smith JR, Freije D, Carpten JD, Gronberg H, Xu JF, Isaacs SD, Brownstein MJ, Bova GS, Quo H, Bujnovszky P, Nusskern DR, Damber JE, Bergh A, Emanuelsson M, Kallioniemi OP, Walkerdaniels J, Baileywilson JE, Beaty TH, Meyers DA, Walsh PC, Collins FS, Trent JM, and Isaacs WB (1996). Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274: 1371-1374.
59. Sonsmall t antigen E, Fedorov S, Kamibayashi C, Robbins D, Cobb M, and Mumby M (1993). The interaction of SV40 small tumor antigen with protein phosphatase 2A stimulates the map kinase pathway and induces cell proliferation. Cell 75:887-897.
60. Tan J, Sharief Y, Hamil KG, Gregory CW, Zang D-E, Sar M, Gumerlock PH, de Vere White RW, Pretlow TG, Harris SE, Wilson EM, Mohler JL, and French FS (1997). Dehydroepiandrosterone activates mutant androgen receptors ex-pressed in the androgen dependent humlan prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 11:450-459.
61. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, and Balk SP (1995). Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393-1398.
62. Tehranian A, Morris DW, Min BH, Bird DJ, Cardiff RD, and Barry PA (1996). Neoplastic transformation of prostatic and urogenital epithelium by the polyoma virus middle T gene. Am J Pathol 149:1177-1191.
63. Thompson TC (1993). Genetic predisposition and mesenchymal-epithelial interactions in ras+myc-induced carcinogenesis in reconstituted mouse prostate. Mol Carcinog 7:165-179.
64. Tilley WD, Buchanan G, Hickey TE, and Bentel JM (1996). Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 2:277-285.
65. Tutrone RFJ, Ball RA, Ornitz DM, Leder P, and Richie JP (1993). Benign prostatic hyperplasia in a transgenic mouse: A new hormonally sensitive investigatory model. J Urol 149: 633-639.
66. Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper GG, Jenster G, Trapman J, Brinkmann AO, and Mulder E (1992). The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 41:665-669.
67. Veltri RW, Partin AW, Epstein JE, Marley GM, Miller CM, Singer DS, Patton KP, Criley SR, and Coffey DS (1994). Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 Image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression. J Cell Biochem 19(Suppl):249-258.
68. Watanabe G, Howe A, Lee RJ, Albanese C, Shu IW, Karnezis AN, Zon L, Kyriakis J, Rundell K, and Pestell RG (1996). Induction of cyclin D1 by simian virus 40 small tumor antigen. Proc Natl Acad Sci USA 93:12861-12866.
69. Wheat WH, Roesler WJ, and Klemm DJ (1994). Simian virus 40 small tumor antigen inhibits dephosphorylation of protein kinase A-phosphorylated CREB and regulates CREB transcriptional stimulation. Mol Cell Biol 14:5881-5890.
70. Wilding G (1992). The importance of steroid hormones in prostate cancer. Cancer Surv 14:113-130.
71. Van Y, Sheppard PC, Kasper S, Lin L, Hoare S, Kapoor A, Dodd JG, Duckworth ML, and Matusik RJ (1997). A large fragment of the probasin promoter targets high levels of transgene expression to the prostate of transgenic mice. Prostate 32:129-139.